Literature DB >> 7386491

Cardiac depression by intravenous disopyramide in patients with left ventricular dysfunction.

A J Leach, J E Brown, P W Armstrong.   

Abstract

The hemodynamic effects of disopyramide phosphate were studied in nine patients with left ventricular dysfunction. After control measurements, administration of a 2 mg/kg bolus of disopyramide phosphate over 5 or 15 minutes was followed by a 20 minute 0.4 mg/kg/hour infusion and a 15 minute recovery period. Response to the 5 and 15 minute bolus injection was similar. Maximum hemodynamic effects occurred immediately after the bolus was given; there were decrements in systolic pressure (142 to 124 mm Hg)(p less than 0.005), cardiac index (2.5 to 1.8 liters/min/m2)(p less than 0.001) and stroke index (29.4 to 20.6 ml/beat/m2)(p less than 0.001), and increases in right atrial pressure (9 to 12 mm Hg)(p less than 0.005) and total peripheral resistance (21.2 to 25.7 U)(p less than 0.005). Two studies had to be terminated after the bolus was given due to profound hemodynamic deterioration. In the remainder, the systolic pressure returned to control by the end of the infusion, whereas the mean arterial pressure increasd significantly (92 to 96 mm Hg)(p less than 0.01). Little further change in mean arterial pressure, cardiac and stroke index, and total peripheral resistance occurred during the recovery period. These data indicated that intravenous disopyramide phosphate is a potent cardiac depressant when given over 5 to 15 minutes to patients with left ventricular dysfunction. It is concluded that disopyramide should not be administered to such patients unless conventional therapy fails. In such circumstances it should be used with extreme caution and careful monitoring.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7386491     DOI: 10.1016/0002-9343(80)90203-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  7 in total

1.  Systolic time intervals in evaluation of the negative inotropic effect after single oral doses of mexiletine and disopyramide.

Authors:  D Rousson; C Piolat; J Galleyrand; S Ferry; J P Boissel
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 2.  New antiarrhythmic drugs: their place in therapy.

Authors:  D L Keefe; R E Kates; D C Harrison
Journal:  Drugs       Date:  1981-11       Impact factor: 9.546

Review 3.  Therapeutic drug monitoring of antiarrhythmic agents.

Authors:  J E Brown; D G Shand
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

4.  Cardiovascular effects of acute normovolemic hemodilution in rats with disopyramide-induced myocardial depression.

Authors:  F G Estafanous; C E Smith; W M Selim; R C Tarazi
Journal:  Basic Res Cardiol       Date:  1990 May-Jun       Impact factor: 17.165

5.  [Hemodynamic effects of disopyramide on postischemic and normal myocardium].

Authors:  H M Hoffmeister; H P Hörmann; M Beyer; L Seipel
Journal:  Klin Wochenschr       Date:  1990-12-04

Review 6.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

7.  Effects of the Na+ antagonist cibenzoline on left ventricular function of postischemic hearts.

Authors:  H M Hoffmeister; M E Beyer; L Seipel
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.